Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
Investment in response to increased demand for North American-based chemistry services
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
Subscribe To Our Newsletter & Stay Updated
